• About
  • FAQs
  • Myth Busters
  • Interaction Checker
  • Resources
    • Vaccine Update
    • Data & Visualization
    • Scientific Repository
  • Contacts

     

logologologo

MEET THE TEAM 

  • About
  • FAQs
  • Myth Busters
  • Interaction Checker
  • Resources
    • Vaccine Update
    • Data & Visualization
    • Scientific Repository
  • Contacts

MEET THE TEAM 

     

logologologo
  • About
  • FAQs
  • Myth Busters
  • Interaction Checker
  • Resources
    • Vaccine Update
    • Data & Visualization
    • Scientific Repository
  • Contacts

     

logologologo
  • About
  • FAQs
  • Myth Busters
  • Interaction Checker
  • Resources
    • Vaccine Update
    • Data & Visualization
    • Scientific Repository
  • Contacts

IMMUNISE.IN

A multi-disciplinary team comprising of doctors, public health experts and many more to get you the most updated scientifically correct information COVID 19 vaccines.

A novel coronavirus is a new coronavirus that has not been previously identified. The virus causing coronavirus disease 2019 (COVID-19), is not the same as the coronaviruses that commonly circulate among humans and cause mild illness, like the common cold.

ABOUT US

WRITE TO US ON

piindia@immunise.in

Tweets by immunise_india
1 (1)

MULTILINGUAL FAQS

Multilingual communication bridges the gaps and fosters understanding between people.

  • Bengali
  • Gujarati
  • Kannada
  • Malayalam
  • Marathi
  • Odia
  • Punjabi
  • Tamil 
  • Telugu
  • Urdu


MythBusters

As health care systems across the country work rapidly to distribute COVID-19 vaccines as efficiently as possible, there is a lot of myth and misconception about COVID Vaccine.

Know more

Newer Vaccines

Sputnik V®

Sputnik V vaccine has been given emergency use authorization in India. In India, the Russian vaccine will be produced by Dr Reddy’s Laboratories. A recent study found no strong allergies caused by Sputnik V®.

India will produce 850 million doses of the Sputnik V® vaccine every year.

In terms of efficacy, Sputnik V outshines both Covishield® and Covaxin® with 91.6 % effectiveness compared to Covishield’s nearly 90% (global reports) and Covaxin’s 81% (interim 3rd phase trial results).

ZyCoV-D®

DNA plasmid based COVID-19 vaccine being developed by Cadila Healthcare with support from the Biotechnology Industry Research Assistance Council.

Zydus Cadila, focused on discovering and developing NCEs, Novel Biologicals, Biosimilars, and Vaccines, announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D®, has been found to be safe in a Phase I clinical trial in healthy subjects, as confirmed by the independent Data Safety Monitoring Board (DSMB). Zydus has begun the Phase II trial.

Biological E’s Novel Covid-19 Vaccine

Biological E. Limited is conducting a prospective open label randomised Phase-I seamlessly followed by Phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E’s novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule(0, 28D) to healthy volunteers.

BBV154 - Intranasal Vaccine

An intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.

Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19.

Bharat Biotech is conducting a Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers.

Source: https://vaccine.icmr.org.in/covid-19-vaccine

COVOVAX

Indian Council of Medical Research and Serum Institute of India jointly performing a phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults.

Source: https://vaccine.icmr.org.in/covid-19-vaccine

2 (1)

VACCINE UPDATE

August 20, 2021

DBT-BIRAC supported ZyCoV-D developed by Zydus Cadila Receives Emergency Use Authorization

Zydus Cadila received Emergency Use Authorization (EUA) from the Drug Controller General of...
Read More
August 3, 2021

Covaxin works against Delta Plus:

 In the study of  efficacy of the Covaxin vaccine. They have found that despite a slight...
Read More
August 1, 2021

CDSCO expert panel recommends nod to study on mixing doses of Covaxin, Covishield

An expert panel of India’s central drug authority  recommended granting permission to the...
Read More
July 29, 2021

AstraZeneca finds small clot risk after 1st COVID shot, less after 2nd

AstraZeneca’s COVID-19 vaccine carries a small extra risk of rare blood clots with low...
Read More
pi_india_logo_yellow_8eQILlgiD-svg
progressive_foundation
yellow_m
[mailchimpsf_form]

LATEST POSTS

  • DBT-BIRAC supported ZyCoV-D developed by Zydus Cadila Receives Emergency Use Authorization August 20, 2021

Contact Us

PI India
6161, First Floor, Pocket 6,
Sector C, Vasant Kunj,
New Delhi, IN – 110070

Contact: +91-9899509943
Email: piindia@immunise.in

QUICK LINKS

Home

About Us

Disclaimer

Terms and Conditions |Privacy Policy
© 2019 -2020 Sirona. All Rights Reserved.